drugset / Trial / NCT03927105
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Phase 2
Completed
4 enrolled
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
Timeline
- Start
- 2019-04-25
- Primary completion
- 2019-11-01
- Completion
- 2023-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabiralizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |